Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged
behind development of these drugs for treating cancers, due in part from concerns over the …

Our concept of the pathogenesis of chronic lymphocytic leukemia has undergone
remarkable changes during the past decade. This review addresses the latest ideas …

Purpose Survival and progression of mature B-cell malignancies depend on signals from the
B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this …

The B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell
malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of …

Immune cells were traditionally considered as major pro-inflammatory contributors. Recent
advances in molecular immunology prove that immune cell lineages are composed of …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with recognized
variability in clinical outcome, genetic features, and cells of origin. To date, transcriptional …

Mediastinal large B-cell lymphoma (MLBCL) is a recently identified subtype of diffuse large
B-cell lymphoma (DLBCL) that characteristically presents as localized tumors in young …

Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays
a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has …

Clinically acquired resistance is a major challenge in cancer therapies with small-molecule
kinase inhibitors (SMKIs). Gatekeeper mutations in the ATP-binding pocket of kinases are …

The B cell lymphoma-6 (Bcl-6) and Bcl-xL proteins are expressed in germinal center B cells
and enable them to endure the proliferative and mutagenic environment of the germinal …